Clinical effect of sequential therapy with alprostadil and beraprost in elderly patients with clinical diabetic nephropathy

王珊珊,常宝成,单春艳,孔岩,卢军,郑妙艳,杨菊红,任惠珠,王颖

DOI: https://doi.org/10.3760/cma.j.issn.0254-9026.2014.02.011

2014-01-01

Abstract:Objective To observe the curative effect and safety of the sequential therapy with alprostadil injection and beraprost sodium tablets in elderly type 2 diabetic patients on the stage of clinical diabetic nephropathy.Methods 90 elderly T2DM patients on clinical diabetic nephropathy stage were randomly divided into 3 groups:control group(conventional therapy for 4 weeks,n=30),alprostadil group(conventional therapy plus alprostadil injection for 2 weeks and conventional therapy for another 2 weeks,n =30) and sequential therapy group(conventional therapy plus alprostadil injection for 2 weeks and conventional therapy plus beraprost sodium tables for another 2 weeks,n=30).The levels of urine albumin(UMA),urine total protein(UTP),urine 6-ketoprostaglandin F1 alpha (6-keto-PGF1α) and urine thromboxane B2 (TXB2).were tested before and 4 weeks after corresponding therapies.Results In alprostadil group and sequential therapy group,the levels of UMA and UTP were significantly decreased 4 weeks after treatment as compared with pre-treatment [UMA:(453.9±90.2) mg/24 h vs.(404.7±60.3) mg/24 h,(465.9±85.4) mg/24 h vs.(340.1± 60.8) mg/24 h; UTP:(2.17±0.51) g/24 h vs.(1.72±0.47) g/24 h,(2.21±0.48) g/24 h vs.(1.44 ±0.39) g/24 h; respectively,all P＜0.01].The decreases in UMA and UTP levels were more obvious in sequential therapy group than in alprostadil group(UMA:25.6％ vs.9.7％ ; UTP:35.0％ vs.16.0％ ; both P＜0.05).The resistive index(RI) in major renal arteries(MRA),segmental renal arteries(SRA) and interlobar renal arteries(IRA) were significantly decreased in alprostadil group and sequential therapy group after treatment as compared with pre-treatment [MRA:(0.70 ± 0.04) vs.(0.75±0.05),(0.68±0.03) vs.(0.74±0.03); SRA:(0.66±0.04) vs.(0.70±0.04),(0.63± 0.03) vs.(0.70±0.04); IRA:(0.62±0.03) vs.(0.66±0.04),(0.60±0.04) vs.(0.66±0.04); respectively,all P＜0.01],and more obvious decreases in the RI in MRA,SRA and IRA were found in sequential therapy group than in alprostadil group(MRA:6.8％ vs.8.2％,SRA:5.8％ vs.9.7％,IRA:6.3％ vs.9.1％,all P＜0.05).Inalprostadil group and sequential therapy group,urine 6-keto-PGF1α level was increased from(261.4±43.9) ng/24 h to(288.7±39.7) ng/24 h and (251.9±47.6) ng/24 h to(313.7±50.2) ng/24 h,whereas urine TXB2was decreased from(172.4±33.5) ng/24 h to (152.1±31.6) ng/24 h,and from(177.3±28.8) ng/24 h to(130.6±34.7) ng/24 h respectively.The changes in urine 6-keto-PGF1α and TXB2 levels were more significant in sequential therapy group than in the alprostadil group (urine 6-keto-PGF1α:29.6％ vs.13.5％,urine TXB2:27.0％ vs.11.9％,both P＜0.05).No significant differences in these indicators were found in the control group before and after the treatment.Conclusions Sequential therapy with alprostadil injection and beraprost sodium tablets may effectively and securely reduce urinary albumin through regulating the renal hemodynamics and the balance of TXA2 and PGI2 in elderly type 2 diabetic patients on clinical diabetic nephropathy stage.